Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCENTIVE-QIV-3-EU influenza vaccine immunogenicity study in infants aged 6 to 8 months
2021-003760-27Phase 4Completed
- Sponsor
- Université libre de Bruxelles
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quadrivalent influenza vaccine in influenza, sponsored by Université libre de Bruxelles. Primary endpoint: HAI antibody titres on Day 0 and Day 58. Started Jul 2021; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2021-003760-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003760-27.